The CPNP USP <800> Compliance Toolkit includes assessments of risk on the formulations listed below. To request additional formulations, simply email the CPNP Office, and they will be considered.
- Abacavir, Solution
- Abacavir, Tablet
- Abacavir/Dolutegravir/Lamivudine, Tablet
- Abacavir/Lamivudine, Tablet
- Abacavir/Lamivudine/Zidovudine, Tablet
- Acitretin, Capsule
- Anastrozole, Tablet
- Azathioprine, Injection
- Azathioprine, Tablet
- Bexarotene, Capsule
- Bicalutamide, Tablet
- Cabergoline, Tablet
- Capecitabine, Tablet
- Carbamazepine, Capsule, XR
- Carbamazepine, Suspension
- Carbamazepine, Tablet
- Carbamazepine, Tablet, Chew
- Carbamazepine, Tablet, XR
- Clomiphene, Tablet
- Clonazepam, Oral Disintegrating Tablet
- Clonazepam, Tablet
- Colchicine, Capsule
- Colchicine, Tablet
- Cyclosporine, Capsule
- Cyclosporine, Ophthalmic
- Cyclosporine, Solution
- Dinoprostone, Vaginal Suppository
- Divalproex, Sprinkles
- Divalproex, Tablet DR & ER
- Dronedarone, Tablet
- Dutasteride, Capsule
- Entecavir, Solution
- Entecavir, Tablet
- Eslicarbazepine, Tablet
- Estradiol, Gel
- Estradiol, Patch
- Estradiol, Spray, Topical
- Estradiol, Tablet
- Estradiol, Vaginal Cream
- Estradiol, Vaginal Insert
- Estrogen/Progestin Combinations, Patch
- Estrogen/Progestin Combinations, Tablet
- Estrogens, Conjugated, Injection
- Estrogens, Conjugated, Tablet
- Estrogens, Conjugated, Vaginal Cream
- Exemestane, Tablet
- Finasteride, Tablet
- Fingolimod, Capsule
- Fluconazole, IV
- Fluconazole, Suspension
- Fluconazole, Tablet
- Fluorouracil, Cream
- Fluorouracil, Solution, Topical
- Flutamide, Capsule
- Fosphenytoin, IV
- Hydroxyurea, Capsule
- Hydroxyurea, Tablet
- Leflunomide, Tablet
- Letrozole, Tablet
- Liraglutide Recombinant, Injection
- Medroxyprogesterone, Injection
- Medroxyprogesterone, Tablet
- Megestrol, Liquid
- Megestrol, Tablet
- Mercaptopurine, Tablet
- Methimazole, Tablet
- Methotrexate, Solution
- Methotrexate, Tablet
- Methyltestosterone, Capsule
- Methyltestosterone, Tablet
- Misoprostol, Tablet
- Mycophenolate Mofetil, IV
- Mycophenolate Mofetil, Liquid
- Mycophenolate Mofetil, Tablet/Capsule
- Mycophenolic Acid, Tablet
- Nevirapine, Suspension
- Nevirapine, Tablet
- Nevirapine, Tablet ER
- Oxcarbazepine, Suspension
- Oxcarbazepine, Tablet
- Paroxetine, Suspension
- Paroxetine, Tablet
- Paroxetine, Tablet ER
- Phenytoin, Capsule
- Phenytoin, Suspension
- Phenytoin, Tablet, Chew
- Progesterone, Capsule
- Progesterone, Injection
- Progesterone, Vaginal Insert & Suppository
- Propylthiouracil, Tablet
- Raloxifene, Tablet
- Ribavirin, Capsule
- Ribavirin, Solution
- Ribavirin, Tablet
- Sirolimus, Solution
- Sirolimus, Tablet
- Sorafenib, Tablet
- Spironolactone, Tablet
- Tacrolimus, Capsule
- Tacrolimus, Capsule XR/Tablet XR
- Tacrolimus, Ointment
- Tamoxifen, Solution
- Tamoxifen, Tablet
- Temazepam, Capsule
- Testosterone, Gel
- Testosterone, Injection
- Testosterone, Patch
- Testosterone, Solution, Topical
- Thalidomide, Capsule
- Topiramate, Capsule ER/Tablet ER
- Topiramate, Sprinkle
- Topiramate, Tablet
- Tretinoin, Capsule
- Tretinoin, Gel/Cream/lotion
- Valganciclovir, Solution
- Valganciclovir, Tablet
- Valproic Acid/Valproate, Capsule
- Valproic Acid/Valproate, Injection
- Valproic Acid/Valproate, Solution
- Vigabatrin, Packet, Oral
- Vigabatrin, Tablet
- Voriconazole, Injection
- Voriconazole, Suspension
- Voriconazole, Tablet
- Warfarin, Tablet
- Zidovudine, Capsule
- Zidovudine, IV
- Zidovudine, Syrup
- Zidovudine, Tablet
- Ziprasidone, Capsule
- Ziprasidone, Injection
- Zoledronic Acid, IV
- Zonisamide, Capsule
Formulations with Pending Assessments of Risk
To request additional formulations, simply email the CPNP Office, and they will be considered.
We are monitoring the NIOSH 2020 update, but it has yet to be finalized. Once finalized, potential additions to the toolkit include Exenatide, Interferon Beta 1-B, Clobazam, Triazolam, Isotretinoin, and others. While the list remains in draft, these Assessments of Risk will not be developed.
Removed Formulations
The following formulations have been removed from the toolkit due to a change of designation that excludes them from the USP <800> compliance process.
Omitted: Medications NOT Eligible for Assessments of Risk
USP 800 allows an assessment of risk to be completed on all medications on Table 2: Non-antineoplastic Hazardous Drugs and Table 3: Non-antineoplastic Drugs that primarily have adverse reproductive effects. However, for medications on Table 1: Antineoplastic Drugs, an assessment of risk is only allowed if the product is a solid dosage form. For all other medications on Table1: Antineoplastic Drugs, full compliance with all standards in USP 800 is required. Table 1 medications are listed below, but the latest complete list can always be found in the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings.